Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy.
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
Carbamates
/ therapeutic use
Eligibility Determination
Female
Frailty
Hepatitis C
/ drug therapy
Humans
Imidazoles
/ therapeutic use
Insurance, Long-Term Care
Isoquinolines
/ therapeutic use
Japan
Male
Pyrrolidines
/ therapeutic use
Sulfonamides
/ therapeutic use
Valine
/ analogs & derivatives
Frailty
Japanese Cardiovascular Health Study index
Kihon Checklist
hepatitis C virus
long-term care insurance certification
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
22
05
2021
revised:
28
06
2021
accepted:
29
06
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
30
7
2021
Statut:
ppublish
Résumé
Direct-acting antiviral (DAA) therapies for patients with hepatitis C virus (HCV) infection deliver higher cure rates and lower frequencies of adverse events than existing therapies, though DAA treatment costs $45,000-64,000 in Japan. The prognosis of patients who require new long-term care insurance (LTCI) certification is inferior to that of patients who do not. Here, we clarify the factors associated with new LTCI certification in elderly patients with HCV infection who undergo DAA therapy. We retrospectively surveyed 53 patients aged ≥70 years who were treated with DAAs, and evaluated the factors associated with new LTCI certification. Of 53 patients, 10 required new LTCI certification. Age ≥85 years and a modified Japanese Cardiovascular Health Study index ≥2 were independently associated with new LTCI certification. In elderly HCV patients, poor frailty status strongly predicted new LTCI certification after DAA therapy.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Direct-acting antiviral (DAA) therapies for patients with hepatitis C virus (HCV) infection deliver higher cure rates and lower frequencies of adverse events than existing therapies, though DAA treatment costs $45,000-64,000 in Japan. The prognosis of patients who require new long-term care insurance (LTCI) certification is inferior to that of patients who do not. Here, we clarify the factors associated with new LTCI certification in elderly patients with HCV infection who undergo DAA therapy.
PATIENTS AND METHODS
METHODS
We retrospectively surveyed 53 patients aged ≥70 years who were treated with DAAs, and evaluated the factors associated with new LTCI certification.
RESULTS
RESULTS
Of 53 patients, 10 required new LTCI certification. Age ≥85 years and a modified Japanese Cardiovascular Health Study index ≥2 were independently associated with new LTCI certification.
CONCLUSION
CONCLUSIONS
In elderly HCV patients, poor frailty status strongly predicted new LTCI certification after DAA therapy.
Identifiants
pubmed: 34281883
pii: 41/8/4127
doi: 10.21873/anticanres.15215
doi:
Substances chimiques
Antiviral Agents
0
Carbamates
0
Imidazoles
0
Isoquinolines
0
Pyrrolidines
0
Sulfonamides
0
Valine
HG18B9YRS7
daclatasvir
LI2427F9CI
asunaprevir
S9X0KRJ00S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4127-4131Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.